Hudson Valley Investment Advisors Inc. ADV lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 4,550 shares of the biopharmaceutical company’s stock after selling 2,370 shares during the period. Hudson Valley Investment Advisors Inc. ADV’s holdings in Gilead Sciences were worth $326,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Welch Investments LLC bought a new stake in Gilead Sciences during the third quarter valued at $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences during the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences during the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management boosted its position in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Institutional investors own 77.96% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a report on Monday, February 5th. Leerink Swann decreased their price target on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research note on Wednesday, February 7th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, February 6th. Finally, Bank of America raised their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $87.75.
In other news, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 424,435 shares of company stock valued at $33,602,330. 1.30% of the stock is owned by company insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up $0.34 during mid-day trading on Monday, reaching $81.06. 7,509,509 shares of the company’s stock were exchanged, compared to its average volume of 9,650,000. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $106,190.00, a PE ratio of 10.54, a P/E/G ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. Gilead Sciences’s revenue for the quarter was down 18.7% on a year-over-year basis. sell-side analysts predict that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio is currently 27.05%.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Position Reduced by Hudson Valley Investment Advisors Inc. ADV” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2018/03/13/gilead-sciences-inc-gild-position-decreased-by-hudson-valley-investment-advisors-inc-adv.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.